The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say ...
7don MSN
In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...
On The Readout LOUD, John Maraganore discusses his new startup, and STAT's Megan Molteni tells the latest about "CRISPR baby" ...
Hosted on MSN2d
Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?CRISPR Therapeutics AG (CRSP) closed the last trading session at $48.92, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...
Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...
While the Nobel-winning genome-editing technology CRISPR holds great promise, Duke’s Center for Advanced Genomic Technologies ...
The Roslin Institute for Animal Research turns to gene editing to combat some of the most important diseases in livestock and ...
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...
CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback